Who
George A. Samuel III
General Counsel and Secretary
Company insider
Files Form 4 as: General Counsel and Secretary, Lineage Cell Therapeutics.
In numbers
- Trades disclosed
- 26
- Buys
- 1
- Sells
- 0
- Bought
- $9,000
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Sep 2021
- Last trade
- 5 Mar 2026
- Last filed
- 6 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Mar 2026filed 6 Mar 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 5 Mar 2026filed 6 Mar 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code M | —6,075 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,5042,502 at $1.80 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,075 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,075 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code M | —6,075 | filing |
| 11 Feb 2026filed 13 Feb 2026 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,5042,502 at $1.80 | filing |
| 19 Dec 2025filed 19 Dec 2025 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,735 | filing |
| 19 Dec 2025filed 19 Dec 2025 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code F | $10965 at $1.68 | filing |
| 10 Mar 2025filed 12 Mar 2025 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 11 Feb 2025filed 12 Feb 2025 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,076 at $0.00 | filing |
| 11 Feb 2025filed 12 Feb 2025 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code M | —6,076 | filing |
| 11 Feb 2025filed 12 Feb 2025 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,5862,440 at $0.65 | filing |
| 26 Nov 2024filed 26 Nov 2024 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Bought | $9,00015,000 at $0.60 | filing |
| 7 Mar 2024filed 8 Mar 2024 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
| 11 Feb 2024filed 12 Feb 2024 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,076 at $0.00 | filing |
| 11 Feb 2024filed 12 Feb 2024 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code M | —6,076 | filing |
| 11 Feb 2024filed 12 Feb 2024 | LCTX Lineage Cell TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,6892,490 at $1.08 | filing |
| 9 Mar 2023filed 10 Mar 2023 | LCTX Lineage Cell Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
News
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1.2% – What's Next?LCTX · dailypolitical.com · 17 Oct 2026
0 headlines in the last 90 days name George A. Samuel III; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.